Global General Influenza Diagnostics 麻豆原创 Research Report 2023

Publication ID:

PB504240674

Publication Date:

May 9, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Influenza virus testing is not required to make a clinical diagnosis of Influenza in outpatients with suspected Influenza,Particularly during increased state-run activity when seasonal state-run influenza A and B viruses are circulating in the local community. The traditional detection methods include: RIDT, Viral Culture, DFA, Serological assays.
Highlights
The global General Influenza Diagnostics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for General Influenza Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for General Influenza Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for General Influenza Diagnostics in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of General Influenza Diagnostics include F. Hoffmann-La Roche, Quidel Corporation, Thermo Fisher Scientific, Abbott Laboratories, Becton, Dickinson, and Company, DiaSorin and 产颈辞惭茅谤颈别耻虫, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for General Influenza Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding General Influenza Diagnostics.
The General Influenza Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global General Influenza Diagnostics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the General Influenza Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
F. Hoffmann-La Roche
Quidel Corporation
Thermo Fisher Scientific
Abbott Laboratories
Becton, Dickinson, and Company
DiaSorin
产颈辞惭茅谤颈别耻虫
Segment by Type
RIDT
Viral Culture
DFA
Serological Assays
Segment by Application
Hospitals
Clinical Laboratories
Other End-User
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of General Influenza Diagnostics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global General Influenza Diagnostics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 RIDT
1.2.3 Viral Culture
1.2.4 DFA
1.2.5 Serological Assays
1.3 麻豆原创 by Application
1.3.1 Global General Influenza Diagnostics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinical Laboratories
1.3.4 Other End-User
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global General Influenza Diagnostics 麻豆原创 Perspective (2018-2029)
2.2 General Influenza Diagnostics Growth Trends by Region
2.2.1 Global General Influenza Diagnostics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 General Influenza Diagnostics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 General Influenza Diagnostics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 General Influenza Diagnostics 麻豆原创 Dynamics
2.3.1 General Influenza Diagnostics Industry Trends
2.3.2 General Influenza Diagnostics 麻豆原创 Drivers
2.3.3 General Influenza Diagnostics 麻豆原创 Challenges
2.3.4 General Influenza Diagnostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top General Influenza Diagnostics Players by Revenue
3.1.1 Global Top General Influenza Diagnostics Players by Revenue (2018-2023)
3.1.2 Global General Influenza Diagnostics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global General Influenza Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by General Influenza Diagnostics Revenue
3.4 Global General Influenza Diagnostics 麻豆原创 Concentration Ratio
3.4.1 Global General Influenza Diagnostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by General Influenza Diagnostics Revenue in 2022
3.5 General Influenza Diagnostics Key Players Head office and Area Served
3.6 Key Players General Influenza Diagnostics Product Solution and Service
3.7 Date of Enter into General Influenza Diagnostics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 General Influenza Diagnostics Breakdown Data by Type
4.1 Global General Influenza Diagnostics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global General Influenza Diagnostics Forecasted 麻豆原创 Size by Type (2024-2029)
5 General Influenza Diagnostics Breakdown Data by Application
5.1 Global General Influenza Diagnostics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global General Influenza Diagnostics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America General Influenza Diagnostics 麻豆原创 Size (2018-2029)
6.2 North America General Influenza Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America General Influenza Diagnostics 麻豆原创 Size by Country (2018-2023)
6.4 North America General Influenza Diagnostics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe General Influenza Diagnostics 麻豆原创 Size (2018-2029)
7.2 Europe General Influenza Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe General Influenza Diagnostics 麻豆原创 Size by Country (2018-2023)
7.4 Europe General Influenza Diagnostics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific General Influenza Diagnostics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific General Influenza Diagnostics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific General Influenza Diagnostics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific General Influenza Diagnostics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America General Influenza Diagnostics 麻豆原创 Size (2018-2029)
9.2 Latin America General Influenza Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America General Influenza Diagnostics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America General Influenza Diagnostics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa General Influenza Diagnostics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa General Influenza Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa General Influenza Diagnostics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa General Influenza Diagnostics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Detail
11.1.2 F. Hoffmann-La Roche Business Overview
11.1.3 F. Hoffmann-La Roche General Influenza Diagnostics Introduction
11.1.4 F. Hoffmann-La Roche Revenue in General Influenza Diagnostics Business (2018-2023)
11.1.5 F. Hoffmann-La Roche Recent Development
11.2 Quidel Corporation
11.2.1 Quidel Corporation Company Detail
11.2.2 Quidel Corporation Business Overview
11.2.3 Quidel Corporation General Influenza Diagnostics Introduction
11.2.4 Quidel Corporation Revenue in General Influenza Diagnostics Business (2018-2023)
11.2.5 Quidel Corporation Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Detail
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific General Influenza Diagnostics Introduction
11.3.4 Thermo Fisher Scientific Revenue in General Influenza Diagnostics Business (2018-2023)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Detail
11.4.2 Abbott Laboratories Business Overview
11.4.3 Abbott Laboratories General Influenza Diagnostics Introduction
11.4.4 Abbott Laboratories Revenue in General Influenza Diagnostics Business (2018-2023)
11.4.5 Abbott Laboratories Recent Development
11.5 Becton, Dickinson, and Company
11.5.1 Becton, Dickinson, and Company Company Detail
11.5.2 Becton, Dickinson, and Company Business Overview
11.5.3 Becton, Dickinson, and Company General Influenza Diagnostics Introduction
11.5.4 Becton, Dickinson, and Company Revenue in General Influenza Diagnostics Business (2018-2023)
11.5.5 Becton, Dickinson, and Company Recent Development
11.6 DiaSorin
11.6.1 DiaSorin Company Detail
11.6.2 DiaSorin Business Overview
11.6.3 DiaSorin General Influenza Diagnostics Introduction
11.6.4 DiaSorin Revenue in General Influenza Diagnostics Business (2018-2023)
11.6.5 DiaSorin Recent Development
11.7 产颈辞惭茅谤颈别耻虫
11.7.1 产颈辞惭茅谤颈别耻虫 Company Detail
11.7.2 产颈辞惭茅谤颈别耻虫 Business Overview
11.7.3 产颈辞惭茅谤颈别耻虫 General Influenza Diagnostics Introduction
11.7.4 产颈辞惭茅谤颈别耻虫 Revenue in General Influenza Diagnostics Business (2018-2023)
11.7.5 产颈辞惭茅谤颈别耻虫 Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

F. Hoffmann-La Roche
Quidel Corporation
Thermo Fisher Scientific
Abbott Laboratories
Becton, Dickinson, and Company
DiaSorin
产颈辞惭茅谤颈别耻虫

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.